BLAINJECTIONINJECTABLE2 Generics Approved
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NOVOLIN 70/30 (human insulin) by Novo Nordisk. Approved for insulin [epc]. First approved in 1991.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLIN 70/30 is a fixed-ratio combination of 70% NPH (intermediate-acting) and 30% regular (rapid-acting) human insulin approved in 1991 for Type 1 and Type 2 diabetes. It works by regulating glucose metabolism through stimulation of peripheral glucose uptake and inhibition of hepatic glucose production. This is a mature, established insulin product delivered via subcutaneous injection.
LOE Approaching
Product approaching loss of exclusivity with competitive pressure at 30%; team focus likely shifting to cost management, market defense, or transition planning.
Mechanism of Action
Pharmacologic Class:
Insulin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
Started Dec 2025
80 enrolled
Metabolic HealthInsulin Sensitivity/Resistance
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
Started Apr 2016
36 enrolled
Type 1 Diabetes Mellitus
A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
Started Aug 2014
38 enrolled
Diabetes Mellitus Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Started Apr 2014
24 enrolled
Diabetes Mellitus, Type 1
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Started Jun 2013
161 enrolled
DiabetesDiabetes Mellitus, Type 2
Worked on NOVOLIN 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.